Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 13, 2023 16:11 ET | Source: Molecular Templates, Inc.

Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update

AUSTIN, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
November 02, 2023 16:11 ET | Source: Molecular Templates, Inc.

Molecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors

AUSTIN, Texas, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics...
November 01, 2023 16:12 ET | Source: Molecular Templates, Inc.

Molecular Templates to Participate in Upcoming Investor Conferences

AUSTIN, Texas, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
September 28, 2023 16:11 ET | Source: Molecular Templates, Inc.

Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer

AUSTIN, Texas, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics...
August 11, 2023 11:22 ET | Source: Molecular Templates, Inc.

Molecular Templates Announces 1-for-15 Reverse Stock Split

AUSTIN, Texas, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM) (the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with...
August 10, 2023 08:08 ET | Source: Molecular Templates, Inc.

Molecular Templates, Inc. Reports Second Quarter 2023 Financial Results and Business Update

AUSTIN, Texas, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
August 02, 2023 16:11 ET | Source: Molecular Templates, Inc.

Molecular Templates Announces Executive Leadership Changes

Dr. Gabriela Gruia to assume the role of interim Chief Medical OfficerJason Kim to assume the role of President and Chief Financial OfficerKristen Quigley to assume the role of Chief Operating...
July 13, 2023 08:14 ET | Source: Molecular Templates, Inc.

Molecular Templates Announces Up to $40 Million Private Placement Offering

AUSTIN, Texas, July 13, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
June 16, 2023 20:56 ET | Source: Molecular Templates, Inc.

Molecular Templates Announces Debt Payoff and Restructuring

Restructuring agreement with K2 HealthVentures (K2HV) to fully discharge and satisfy outstanding debt owed to K2HV for the prepayment of $27.5 million and the granting of contingent value rights and...
June 01, 2023 07:57 ET | Source: Molecular Templates, Inc.

Molecular Templates Announces the FDA Removal of Partial Clinical Hold in the Phase 1 Clinical Trial for MT-0169 and Focuses on Extramedullary Myeloma

AUSTIN, Texas, June 01, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...